jamunjar-logo
whatsapp
cartmembermenu
Search for
"test & packages"
"physiotherapy"
"heart"
"lungs"
"diabetes"
"kidney"
"liver"
"cancer"
"thyroid"
"bones"
"fever"
"vitamin"
"iron"
"HTN"

Arm swelling biopsy - Medium 1-3 cm

Biopsy
image

Report in 288Hrs

image

At Home

nofastingrequire

No Fasting Required

Details

Biopsy of swelling in arm.

₹370₹529

30% OFF

Arm Swelling Biopsy - Medium 1-3 cm: Comprehensive Medical Test Guide

  • Section 1: Why is it done?
    • Test Purpose: This biopsy procedure involves the removal and microscopic examination of tissue from a 1-3 cm lesion or swelling on the arm to determine the nature and cause of the abnormality
    • Primary Indications: To differentiate between benign and malignant lesions, identify infectious or inflammatory conditions, diagnose dermatological disorders, evaluate suspicious skin growths, or confirm clinical diagnoses when imaging is inconclusive
    • Common Reasons for Ordering: Unexplained arm swelling, nodules, lumps, discolored patches, ulcerations, suspected melanoma or other skin cancers, suspected lymphoma, persistent edema with unknown etiology, or lesions that have changed in appearance or size
    • Typical Timing: Performed when physical examination reveals a suspicious lesion, after imaging studies have been completed, or when clinical suspicion for malignancy exists. Usually performed within weeks to months of lesion detection depending on urgency
  • Section 2: Normal Range
    • Normal/Benign Results: Histological findings consistent with benign tissue such as lipoma (benign fat tumor), epidermoid cyst, seborrheic keratosis, hemangioma (benign blood vessel growth), or normal dermal tissue without evidence of malignancy or significant pathology
    • Abnormal/Positive Results: Histological evidence of malignancy, atypical cells, dysplasia, malignant melanoma, non-melanoma skin cancer, lymphoma, sarcoma, metastatic disease, or infectious organisms (fungal, bacterial, or parasitic)
    • Result Interpretation Categories: Negative (Benign) - No evidence of malignancy; Positive/Malignant - Evidence of cancer; Atypical/Borderline - Uncertain significance requiring further evaluation; Inflammatory - Non-specific inflammation without malignancy; Infectious - Organisms identified suggesting infection
    • Units of Measurement: Microscopic examination reported in millimeters (mm) for lesion size; histological classification using standard pathological nomenclature; immunohistochemical markers expressed as percentage of positive cells; mitotic rate reported as number per high-power field
  • Section 3: Interpretation
    • Benign Findings: Indicates no malignancy detected. Common benign diagnoses include lipomas (soft tissue tumors of fat), seborrheic keratosis (benign skin growth), epidermoid cysts (non-cancerous cysts), hemangiomas (benign vascular lesions), or neurofibromas (benign nerve sheath tumors). Generally does not require aggressive treatment but may require monitoring
    • Malignant Findings: Confirms presence of cancer requiring immediate clinical intervention. Results will specify type of malignancy (melanoma, squamous cell carcinoma, basal cell carcinoma, lymphoma, sarcoma) and grade/stage when applicable. May require surgical resection, chemotherapy, radiation, or targeted therapy
    • Atypical/Dysplastic Findings: Indicates cellular abnormalities that are not definitively malignant but show concerning features. May represent precancerous changes (dysplasia) or atypical nevus. Requires close follow-up, repeat biopsy if margins unclear, and increased surveillance for malignant transformation
    • Inflammatory Findings: Demonstrates inflammatory cell infiltration suggesting dermatitis, eczema, psoriasis, or other inflammatory skin conditions. Treatment typically involves topical or systemic anti-inflammatory medications and management of underlying cause
    • Infectious Findings: Identifies causative organisms including bacteria, fungi (including fungal cultures), parasites, or viral inclusion bodies. Guides specific antimicrobial or antifungal therapy based on organism identified
    • Factors Affecting Interpretation: Specimen adequacy and depth of sampling, site of biopsy (lesion center vs. edge), presence of ulceration or necrosis, patient age and skin type, prior treatments affecting tissue appearance, immunosuppression status, previous biopsies or radiation therapy to area
    • Grading Systems: Breslow thickness (for melanoma, measured in millimeters), Clark level (depth of invasion), Fuhrman grade (nuclear grade for renal cell carcinoma), histological grade (well/moderately/poorly differentiated), and TNM staging when applicable
  • Section 4: Associated Organs
    • Primary Organ System: Integumentary system (skin and subcutaneous tissue). The arm contains epidermis, dermis, hypodermis, as well as underlying muscles, fascia, lymph nodes, and blood vessels that may be involved in pathological processes
    • Conditions Associated with Abnormal Results: Melanoma, squamous cell carcinoma, basal cell carcinoma, cutaneous lymphoma, soft tissue sarcoma, metastatic cancer (from lung, breast, kidney), cellulitis, erysipelas, lymphedema, lipedema, necrotizing fasciitis, fungal infections, parasitic infestations, inflammatory dermatoses
    • Diseases Diagnosed or Monitored: Cutaneous malignancies, systemic lymphomas with skin involvement, infectious diseases (tuberculosis verrucosa cutis, leprosy, fungal infections), autoimmune conditions (sarcoidosis, lupus erythematosus), benign skin tumors, and metastatic disease from internal organs
    • Associated Lymph Nodes: Axillary (underarm) lymph nodes drain the arm and may be involved with metastatic disease or systemic conditions. Lymphatic involvement can indicate advanced disease and affect staging and prognosis
    • Potential Complications of Abnormal Results: Local tumor spread, regional lymph node involvement, distant metastasis (lungs, liver, brain, bone), sepsis if infectious, systemic infection, pathological fracture if bone involved, lymphedema from lymph node removal, compromised limb function, psychological distress from malignancy diagnosis
    • Secondary Organ Involvement: Cutaneous manifestations of systemic diseases may indicate involvement of lymph nodes, liver, spleen, or other organs. For instance, cutaneous lymphoma may herald systemic lymphoma; metastatic skin lesions may originate from internal malignancies
  • Section 5: Follow-up Tests
    • If Benign Result: Clinical reassurance and observation; repeat imaging if rapid growth; physical examination at routine intervals; additional biopsy only if significant changes in lesion characteristics occur or symptoms develop
    • If Malignant Result: Wide surgical excision of primary tumor with appropriate margins; staging studies including CT chest/abdomen/pelvis, PET-CT scan, MRI for depth assessment, sentinel lymph node biopsy, complete blood count, metabolic panel, lactate dehydrogenase (LDH) levels
    • If Atypical/Dysplastic Result: Repeat biopsy with wider sampling or full surgical excision; dermatology consultation; close clinical monitoring every 3-6 months; photographic documentation for comparison; genetic testing if hereditary syndrome suspected (BRAF, NRAS mutations for melanoma)
    • If Infectious Result: Culture and sensitivity testing, fungal culture with speciation, bacterial culture, serological testing for specific organisms, inflammatory markers (ESR, CRP), immune function studies if recurrent infections, imaging to assess extent of infection
    • Complementary/Confirmatory Tests: Immunohistochemical staining (HMB45, S100, Melan-A for melanoma confirmation), flow cytometry for lymphomas, molecular testing (BRAF, NRAS, KIT, ALK gene analysis), electron microscopy for ultrastructural assessment
    • Monitoring Frequency for Confirmed Malignancy: Melanoma: every 3-6 months for first 2 years, then every 6-12 months; non-melanoma skin cancers: annual examination minimum; lymphomas: every 1-3 months depending on stage and treatment; follow-up imaging as directed by oncologist based on stage
    • Related Diagnostic Tests: Ultrasound of arm for deeper assessment, MRI for soft tissue characterization, CT scan for staging, PET-CT for metastatic disease, dermoscopy for pigmented lesions, side-view photography, complete skin examination, axillary lymph node assessment
  • Section 6: Fasting Required?
    • Fasting Requirement: NO - Fasting is not required for this procedure as it is a localized tissue biopsy and does not require blood work or laboratory analysis that would necessitate fasting
    • Anesthesia Considerations: Local anesthesia used; if procedural sedation required, fasting 6-8 hours prior may be recommended depending on anesthetic protocol. Follow specific pre-procedure instructions from facility
    • Medications to Avoid: Discontinue anticoagulants (warfarin, dabigatran) 3-5 days prior if possible; stop antiplatelet agents (aspirin, clopidogrel, NSAIDs) 3-7 days before procedure to reduce bleeding risk; consult with physician regarding continuation of critical medications; provide complete medication list at time of procedure
    • Pre-Procedure Preparation: Wash area with mild soap and water morning of procedure; do not apply lotions, powders, or cosmetics to biopsy site; wear loose-fitting clothing allowing easy access to arm; bring insurance card and photo identification; arrive 15 minutes early
    • Post-Procedure Instructions: Keep bandage in place for 24-48 hours; avoid strenuous activity for 7-10 days; do not submerge wound in water; gently clean with soap and water; apply antibiotic ointment as directed; watch for signs of infection (increased redness, warmth, drainage, fever)
    • Special Considerations: Notify provider of bleeding disorders, keloid history, allergies to local anesthetics (especially lidocaine), pregnancy, immunosuppression, or recent systemic infection; arrange transportation if sedation planned; schedule results discussion with physician

How our test process works!

customers
customers